Recombinant Cynomolgus CD19/CD19 Molecule (C-Fc)
|Amount :||50 µg|
|Content :||Lyophilized from a 0.2 µm filtered solution of PBS, pH7.4.|
|AA sequence :||Recombinant Cynomolgus CD19 Molecule is produced by our Mammalian expression system and the target gene encoding Pro20-Lys292 is expressed with a Fc tag at the C-terminus.|
|Alternative Name :||B-Lymphocyte Antigen CD19; B-Lymphocyte Surface Antigen B4; Differentiation Antigen CD19; T-Cell Surface Antigen Leu-12; CD19|
CD19 is a single-pass type I membrane protein containing 2 Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. CD19 primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. CD19 Assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. Defects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) which is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.